reference/14062484

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14062484

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural
endingPage	1215
issn	1573-0646 0167-6997
issueIdentifier	3
pageRange	1211-1215
publicationName	Investigational New Drugs
startingPage	1211
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5f7f17266abb8e53e62d8d2feb5c41c3 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ca11c36ff38920813f98c6faeb13aec2 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e6334f9ea25bb27e041f1ec3927dab3f
bibliographicCitation	Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs. 2011 May 07;30(3):1211–5. doi: 10.1007/s10637-011-9681-x.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a9aa3795cde62ff2a06826595877251d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_30e9a737abee2954144b5f56eb0a56b0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_18921e50e5e182eb96ffaf2b86962086 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_41fe6d9ca0662d9ee50e8102478cb22b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fc75ee2a4800c6fcd7e7c98e5f70b3cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_328dce0279a57c4d7240794c209968c1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d436714a0168b28418c18ea736c30e5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8a058f88ce52d67ced98757d70380b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5766aeee04e65b9afa3d1f9125a88319 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2654c77cf5cf45ddd16437127d3bf083 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_980934b62732e15f847841d95ee625c2
date	2011-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/21552992 https://doi.org/10.1007/s10637-011-9681-x https://pubmed.ncbi.nlm.nih.gov/PMC4317401
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372 https://portal.issn.org/resource/ISSN/1573-0646 https://portal.issn.org/resource/ISSN/0167-6997
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
discusses	http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0028454 http://id.nlm.nih.gov/mesh/M0470497
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID141643 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9887053 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6873 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3062316

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129879136 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129281950 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129555111

Total number of triples: 58.